Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,639 INR | +0.12% | +1.42% | +23.90% |
13/05 | Lupin Relaunches Mirabegron ER Tablets in US | MT |
09/05 | Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy | MT |
Sales 2024 | 200B 2.4B | Sales 2025 * | 217B 2.6B | Capitalization | 747B 8.96B |
---|---|---|---|---|---|
Net income 2024 | 19.14B 230M | Net income 2025 * | 23.97B 287M | EV / Sales 2024 | 3.68 x |
Net Debt 2024 * | 24.9B 299M | Net Debt 2025 * | 8.41B 101M | EV / Sales 2025 * | 3.49 x |
P/E ratio 2024 |
38.6
x | P/E ratio 2025 * |
31.2
x | Employees | 20,933 |
Yield 2024 * |
0.44% | Yield 2025 * |
0.51% | Free-Float | 52.83% |
Latest transcript on Lupin Limited
1 day | +0.12% | ||
1 week | +1.42% | ||
Current month | -0.41% | ||
1 month | +1.86% | ||
3 months | +2.12% | ||
6 months | +40.06% | ||
Current year | +23.90% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 01/97/01 | |
Johnny Mikell
PSD | President | - | - |
Director of Finance/CFO | 59 | 13/07/13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 27/15/27 | |
Mark McDade
BRD | Director/Board Member | 69 | 28/21/28 |
Director/Board Member | 50 | 01/96/01 |
Date | Price | Change | Volume |
---|---|---|---|
15/24/15 | 1,639 | +0.12% | 559,501 |
14/24/14 | 1,637 | -3.05% | 1,028,097 |
13/24/13 | 1,689 | +4.98% | 2,246,490 |
10/24/10 | 1,609 | +1.55% | 731,066 |
09/24/09 | 1,584 | -1.99% | 883,851 |
Delayed Quote NSE India S.E., May 15, 2024 at 05:13 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- LUPIN Stock
- LUPIN Stock